Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Mar 8, 2024
- Accession no.
- 0001601830-24-000022
- Filed
- Mar 8, 2024
- Trade date
- Mar 6, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 11 non-derivative transactions and 6 derivative transactions. Open-market sales total $719.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 6, 2024 | Class A Common Stock | CConversionAcquired | +10,000 | $0.00 | $0 | 1,114,919 | Direct | |
| Mar 6, 2024 | Class A Common Stock | GGiftDisposed | −10,000 | $0.00 | $0 | 1,104,919 | Direct | |
| Mar 6, 2024 | Class A Common Stock | MOption exerciseAcquired | +31,250 | $2.48 | +$77,500 | 1,136,169 | Direct | |
| Mar 6, 2024 | Class A Common Stock | MOption exerciseAcquired | +8,674 | $11.40 | +$98,883.6 | 1,144,843 | Direct | |
| Mar 6, 2024 | Class A Common Stock | SSaleDisposed | −36,319 | $11.86F3 | −$430,743.34 | 1,108,524 | Direct | |
| Mar 6, 2024 | Class A Common Stock | CConversionAcquired | +4,000 | $0.00 | $0 | 4,000 | Indirect | |
| Mar 6, 2024 | Class A Common Stock | SSaleDisposed | −4,000 | $11.56F6 | −$46,240 | 0 | Indirect | |
| Mar 6, 2024 | Class A Common Stock | CConversionAcquired | +20,000 | $0.00 | $0 | 20,000 | Indirect | |
| Mar 6, 2024 | Class A Common Stock | SSaleDisposed | −20,000 | $11.55F8 | −$231,000 | 0 | Indirect | |
| Mar 6, 2024 | Class A Common Stock | CConversionAcquired | +1,000 | $0.00 | $0 | 1,000 | Indirect | |
| Mar 6, 2024 | Class A Common Stock | SSaleDisposed | −1,000 | $11.56F10 | −$11,560 | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 6, 2024 | Class A Common Stock | MOption exerciseDisposed | −31,250 | $0.00 | $0 | 312,500 | Direct | |
| Mar 6, 2024 | Class A Common Stock | MOption exerciseDisposed | −8,674 | $0.00 | $0 | 399,002 | Direct | |
| Mar 6, 2024 | Class A Common Stock | CConversionDisposed | −10,000 | $0.00 | $0 | 6,461,496 | Direct | |
| Mar 6, 2024 | Class A Common Stock | CConversionDisposed | −4,000 | $0.00 | $0 | 511,000 | Indirect | |
| Mar 6, 2024 | Class A Common Stock | CConversionDisposed | −20,000 | $0.00 | $0 | 388,000 | Indirect | |
| Mar 6, 2024 | Class A Common Stock | CConversionDisposed | −1,000 | $0.00 | $0 | 117,875 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $11.24 to $12.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $11.32 to $12.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F8
This transaction was executed in multiple trades at prices ranging from $11.22 to $12.09. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F10
This transaction was executed in multiple trades at prices ranging from $11.23 to $12.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.